Clinical Trials Browser

Myeloproliferative Disorders × selinexor × 30 days × Clear all

NCT07626021 2026-06-04

Selinexor Monotherapy for Cytoreduction in BCR::ABL1-Negative Myeloproliferative Neoplasms

Phase 2 Not yet recruiting

Myeloproliferative Disorders